July 2, 2018 – PRESS RELEASE – International precision agriculture provider AgriTask has adapted its novel Agri-platform for use by medical cannabis growers who, unlike other farmers, face a unique regulatory environment. Already in wide use for other crops, the company modified the platform specifically to meet the stringent IMC-GAP regulations for growing medical cannabis.

“Our challenge was to quickly adapt our platform that has been so successful with soybeans, coffee, cotton, various vegetables and in orchards and forestry to a crop that is highly regulated,” says Israel Fraier, chairman and CEO of AgriTask. He adds that “the platform’s flexibility allowed us to take advantage of experience in Brazil, Mexico, Peru and Israel and develop a platform that meets the strictest regulations and at the same time improve productivity and increase yields.”

The AgriTask platform integrates various data sources into one comprehensive, easy-to-use system, which serves all management levels. The company’s proprietary app allows the user to benefit from a full range of integrated inputs including satellite and UAV image layers and indexes, automatic climate models, digitalization of field data based on individual protocols, and integrating machinery and third-party sensor data. This permits users to easily detect problems in the growing cycle, define a plan and control the entire process from beginning to end.

“AgriTask’s arrival on the scene was perfectly timed for us and has helped in a whole array of tasks from pest surveys to diseases, and from ongoing operations to costs to names just a few,” says Getulio Ferreira, director of planning and production at Girassol Agricola, one of the biggest seed producing companies in Brazil. He adds that the use of AgriTask’s platform “has enabled us to generate more accurate and reliable data for fast and assertive decision making.” In addition, Ferreira notes the platform enabled Girassol Agricola to take the technological era in the field one step further by totally eliminating the use of paper.

The company has taken its highly successful platform used in a full range of crops one step further to meet the stringent regulatory environment facing medical cannabis growers. The upgrading gives the growers the necessary tools to monitor and document every aspect of the process from the mother plant, to post-harvest processing and shipment reports. This includes tracking and documenting of all activities from pest monitoring, to waste and death of plants, mobility of plants at a specific facility, quantities harvested and quality assessment. Data can be entered into the system by farm workers and managers through the proprietary mobile application developed by AgriTask for medical cannabis growers or automatically via integration to alternative systems.

After harvesting, each batch receives a unique ID, which includes details from the mother plant stages, clones taken, the growth cycle, post-harvest, weight, packaging and all relevant laboratory test results. The ID is prepared in accordance with Israeli Health Ministry regulations, which are currently the most stringent in the world for medical cannabis.

This kind of documentation is a crucial part of the regulatory process that growers are facing in the US and Israel as well as other countries in this relatively new segment in agriculture. As a drug, the regulations ensure that the final product meets the stringent quality level for use by patients. No less important is to prevent any seepage of medical cannabis into the non-medical market.

Equally as important for growers are productivity and yields. The AgriTask platform gives growers up to the minute reports that allow real time assessments regarding the state of their batches and risks and immediate action on critical issues ranging from fertilizer, pest and disease treatment, lighting and irrigation to name just a few.

The system’s capabilities raise the overall responsibility of the staff and facilitate data reporting in real time. The quick response to risks and events effecting the growing of medical cannabis enables the prevention of unnecessary chemical applications on the plants, minimizes batch mortality and produces a cleaner, higher quality product for medical use. The bottom line for the growers is higher yields with far lower inputs and fewer losses from regulation.

Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) (“Liberty” or the “Company”) today announced it has received Good Manufacturing Practice (“GMP”) approval from SAI Global for the Company’s ­­greenhouse and production facilities in ­­Alachua County, Florida. The GMP certificate was earned in advance of Liberty’s July 5th deadline for its processing facilities, confirming the site’s compliance with ­­FDA’s food safety and packaging GMPs.

“The Good Manufacturing Practice certification is another testament to our commitment to excellence and precision dosing of cannabis products,” said CEO George Scorsis. “We strive to set the bar for safety, quality and consistency as we expand in response to the rapidly growing need in the emerging cannabis industry. It is a great honor and a privilege to receive a GMP certification compliant to the FDA standard that validates all the exhaustive work our team has done to ensure Liberty products are the very best.”

“In anticipation of expected state approval of edibles, we have built an all-encompassing food safety plan which goes above and beyond regulatory requirements,” said Director of Compliance and Regulatory, Jessica Engle. “We want to give our consumers 100% confidence that the products they purchase are guaranteed safe and this certification reinforces that promise.”

About Liberty Health Sciences Inc.

Liberty Health Sciences Inc. is an investor and operator in the cannabis market, capitalizing on new and existing opportunities in U.S. states where cannabis is legal. Liberty’s stringent investment criteria for expansion maximizes returns to shareholders, while focusing on significant near- and mid-term opportunities while keeping consumers well-being at the forefront of what we do. Liberty has an extensive background in highly regulated industries, with expertise in becoming a low-cost producer. Liberty leverages commercial greenhouse knowledge to deliver high-quality, clean and safe pharmaceutical grade cannabis to consumers.

For more information, please visit libertyhealthsciences.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release contains certain forward-looking statements within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “believe”, “plan”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, expectations related to the production and sale of edible products in Florida, expected state approval of edibles, and the Company’s future expansion and growth strategies. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in the United States generally, income tax and regulatory matters; the ability of Liberty to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

SOURCE Liberty Health Sciences Inc.

 

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Tauriga Sciences, Inc. (OTC PINK: TAUG) (“Tauriga” or the “Company”), engaged in building its business through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today announced the completion of initial purchase order for 4 Level II Electric Vehicle (“EV”) Pedestal Charging Units (“EV Charge Units” or “EV Units”) from NASDAQ listed Blink Charging Co. (“Blink”).  The Company has identified two locations to install these EV Units, which it believes have the potential to attract a substantial level of EV driver traffic.

Recall that on April 27, 2018, Tauriga announced the execution of a Reseller Agreement with Blink to assist Blink in expanding its already significant national electric vehicle charging network.  This Reseller Agreement, which was entered into by Tauriga’s wholly owned subsidiary Tauriga Biz Dev. Corp., provides the Company’s shareholders with a potential revenue opportunity through the sales revenue model expressed in such agreement.  By purchasing units outright, the Company is able to substantially increase its potential revenue share (as pertaining to those specific units that have been purchased and are owned outright by Tauriga).  Once these 4 initial EV Units are installed, the Company will update its shareholders and may opt to purchase additional EV Units over the course of the coming weeks and months.

Please see below, the link to Tauriga’s April 27, 2018 press release disclosing its Reseller Agreement with Blink Charging Co.

Link:https://finance.yahoo.com/news/blink-charging-company-enters-reseller-130000375.html

ABOUT TAURIGA SCIENCES, INC.

Tauriga Sciences, Inc. (OTC PINK: TAUG) is engaged in building business through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities/equity investments. The Company is currently evaluating potential acquisition candidates, as previously disclosed, to create lasting shareholder value. Additionally, the Company is working diligently to identify potential opportunities to generate revenue and leverage its considerable resources and expertise to build a diversified and sustainable business model.  Please visit our corporate website at www.tauriga.com

FORWARD-LOOKING STATEMENTS:

This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events.  These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones.  Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated.  Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other filings made from time to time with the Securities and Exchange Commission.  Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.

Health Canada recently issued a Notice of Intent to Amend the PDL to add phytocannabinoids produced by, or found in, the cannabis plant and substances that are duplicates of such phytocannabinoids. In 2017, Tetra completed a major safety, pharmacokinetic and pharmacodynamic study in healthy human subjects that allowed Tetra to collect significant data to support its marketing applications. A similar clinical development program was launched with cannabis oils in preparation for the upcoming post-legalization market.  The combination of safety, pharmacokinetic and efficacy data allows Tetra to bring products to market under the proposed new regulatory framework.  Tetra Bio-Pharma is one of a few cannabinoid based companies that is committed to providing much needed clinical data for both its pharmaceutical and natural health products.

Over the coming months Tetra Bio-Pharma will deliver its findings in a series of presentations and scientific articles that will be published in 2018 to share the clinical data of both the inhalation and oral clinical development programs with the medical community,  beginning with the July 4, 2018 International Cannabinoid Research Society Meeting in the Netherlands where Dr. Maria-Fernanda Arboleda, MD, will present the results of the above clinical trial. http://www.icrs.co/SYMPOSIUM.2018/ICRS2018.PRELIMINARY.PROGRAMME.pdf ).  Tetra is a Gold Sponsor of this prestigious congress.

Update on North Bud Farms Inc.

Tetra Bio-Pharma has agreed to provide an extension to North Bud Farms Inc. with regards to the receipt of North Bud’s preliminary and final prospectus.  As one of the closing conditions to the sale these documents must now be submitted by July 31, 2018.

About Tetra Bio-Pharma

Tetra Bio-Pharma (TBP.V) (TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

In recent laboratory testing, Lexaria’s breakthrough discovery evidenced greatly enhanced drug delivery to brain tissue. Nicotine in-vivo (animal) studies showed that up to 560% more nicotine was delivered to brain tissue utilizing DehydraTECH^TM than concentration-matched controls lacking DehydraTECH^TM enhancements. The study provided evidence of surprising effectiveness in crossing the blood-brain barrier (“BBB”) which the Company is investigating more extensively, leading to Lexaria’s patent application titled: “Enhancement of Delivery of Lipophilic Active Agents Across the Blood-Brain Barrier and Methods for Treating Central Nervous System Disorders.”

It is well documented that nicotine – while addictive – does not cause cancer. It is the tar and other chemicals formed when cigarettes are combusted that cause cancer. Thus, an efficient delivery mechanism of minute quantities of nicotine that does not require combustion could lead to greatly reduced death and disease through the avoidance of smoking, while also potentially aiding reduced chemical dependence on nicotine until such time as addictive-avoidance behaviours can be empowered.

Lexaria’s surprising discovery of the DehydraTECH^TM apparent effectiveness in crossing the BBB also opens the door to possibilities of delivering other therapeutic drugs in the treatment of intractable diseases.

The BBB, while providing effective protection to the brain against circulating toxins, also creates major difficulties in the pharmacological treatment of brain diseases. Most charged molecules, and most molecules over 700 Daltons in size, are unable to pass through the barrier, and smaller molecules may be conjugated in the liver. These factors create major difficulties in the pharmacological treatment of diseases of the brain and central nervous system (“CNS”), such as Alzheimer’s disease, Parkinson’s disease, bacterial and viral infections and cancer.

Many therapeutic agents for the treatment of diseases and disorders of the brain and CNS are sufficiently hydrophilic to preclude direct transport across the BBB. Furthermore, these drugs and agents are susceptible to degradation in the blood and peripheral tissues that increase the dose necessary to achieve a therapeutically effective serum concentration. However, as described above, although lipophilicity is generally associated with molecules that are easily able to cross the blood-brain barrier, lipophilicity is not the leading characteristic for molecules that transverse the blood-brain barrier. Seelig and colleagues studied the association of different factors with the ability of molecules to diffuse across the blood-brain barrier, including lipophilicity, Gibbs Adsorption Isotherm, a Co CMC Plot, and the surface area of the drug to water and air (Seelig et al. (1994) Proc. Nat. Acad. Sci. (USA) 91:68-72). Their results showed that barrier permittivity is based on a complex interaction between relative size and the surface activity of the molecule, in which the surface activity includes the molecular properties of both hydrophobic and charged residues (Seelig et al. (1994) Proc. Nat. Acad. Sci. (USA) 91:68-72).

Prior methods for delivering drugs across the BBB involve three general categories: (1) liposome-based methods, where the therapeutic agent is encapsulated within the carrier; (2) synthetic polymer-based methods, where particles are created using synthetic polymers to achieve precisely-defined size characteristics; and (3) direct conjugation of a carrier to a drug, where the therapeutic agent is covalently bound to a carrier such as insulin. Liposomes are attractive for transporting drugs across the BBB because of their large carrying capacity. However, liposomes are generally too large to effectively cross the BBB, are inherently unstable, and their constituent lipids are gradually lost by absorption by lipid-binding proteins in the plasma. Synthetic polymers have run into difficulties having the drug carried across the cell only to be trapped in an endothelial cell or a lysosome, instead of the desired result of being ejected into the brain parenchyma.

Cleveland, OH–JUNE 24, 2018 — PRESS RELEASE — The Medical Cannabis Pioneers Picnic will be held at Rid All Green Partnership, a thriving urban farm in Cleveland, Ohio, on July 22, 2018 from 3 p.m. to 7 p.m. Guests will enjoy healthy and organic picnic fare, while several certified-to-recommend doctors from Cleveland/Akron-area private practices discuss their path to recommending cannabis to their patients.

Food and drink included in price of ticket ($16). All children are free. Doctors will be available or patient questions. Cannabis industry businesses and activist organizations will be providing information on the status of Ohio’s medical program and professional opportunities and products. Keynote speakers are Dr. Solomon Zaraa of Compassionate Cleveland and Dr. Janet Levatin of Patient Focus.

A visit to Rid All Farm is always a treat, with “regenerative agriculture” on display amid a campus of greenhouses and orchard in Cleveland’s own “Innovative Agriculture Zone.” Sustainable agriculture talks and tours will be provided by the experts at Rid All. Children’s entertainment will be provided by Magic Nate, energy elixirs provided by Urban Farm Doctor, and food will feature locally-sourced plant-based foods with meat options. Wine-tastings, gift basket raffles, and giveaways throughout the evening.

Midwest CannaWomen is an organization formed by and for women from diverse backgrounds who are pioneering into the Midwest regional cannabis industry. Our mission at Midwest CannaWomen is to provide resources, education, skills training, and unique networking opportunities to women to unify, build a base of support for each other, and to connect with quality opportunities within the industry. Tickets at: https://www.eventbrite.com/e/medical-cannabis-pioneers-picnic-tickets-47119280035

Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV:N.V)(M5BQ.F)(NXTTF) is pleased to announce signing of a Master Services Agreement (the “Agreement”) with YPB Group Ltd. (“YPB”)(YPB.AX), an Australian based product verification and customer engagement company. Namaste has identified the need for its global customers to have confidence in the products they are purchasing, and for vendors to have access to granular data on their end-users. As such, Namaste plans to introduce YPB’s solutions across its network of manufacturers and to Canadian Licensed Producers to bring certainty of authenticity and supply chain transparency to the entire legal cannabis industry globally. This coalition furthers Namaste’s agenda in providing leading technology platforms for its global marketplace and in enhancing the user’s experience for its customers.

Namaste is the world’s largest and most comprehensive cannabis-focused e-commerce platform with 32 sites in 20 countries and over 600,000 monthly visits to their e-commerce sites with a database of approximately 1.5 million users. Their fully integrated e-commerce network spans across the globe offering everything from rolling papers to vaporizers. In Canada , Namaste has developed the country’s first telemedicine app, available on iPhone and Android devices which allows patients to connect to doctors or nurse practitioners and have access to a wide range of high-quality cannabis products and services. The shared strategy of this Agreement is to leverage Namaste’s market position with the objective that all vendors on its platform across the entire cannabis supply chain will adopt this technology and mark every product with YPB ProtectCodes to help protect consumers by ensuring the products and services they are purchasing are safe and reliable.

Sean Dollinger , President, and CEO of Namaste comments: “Our extensive tender process identified Australian-based company YPB as being able to deliver the most sophisticated forensic level anti-counterfeit security for brand protection. We are confident YPB’s Secure Supply Chain tracking will enhance trust in the legitimacy and integrity of the vast range of products and services being sold throughout the industry. Namaste has spent years building strong, trusted relationships with vendors in the industry many of whom suffer from having their products counterfeited and sold through unlicensed distributors. Through this partnership, Namaste offers an effective solution to further support our vaporizer and hardware vendors. Additionally, we believe this technology has the ability to revolutionize the sale of cannabis throughout the Canadian market, with the potential for global market penetration. We fully intend on leveraging our relationships with licensed producers with the hope of providing additional value to LP’s and their customers. As the market expands and becomes more competitive we expect to see an increased demand for the adoption and implementation of anti-counterfeit security to ensure all parties involved are adequately protected. We believe YPB is a leader in the space and we are excited to work alongside them to come up with unique solutions for the cannabis industry.

]]> https://mjshareholders.com/fdas-approval-of-new-cannabis-derived-drug-will-pave-the-way-for-future-medications-ceo-says/ Wed, 27 Jun 2018 20:40:20 +0000 http://www.cannabisbusinesstimes.com/Article/gw-pharma-fda-new-drug-future-medications

Edmonton, AB – June 26, 2018 – PRESS RELEASE – Aurora Cannabis Inc. announced today that it has agreed to a new $200 million debt facility, with a potential upsize to $250 million, with the Bank of Montreal (“BMO”).

The facility will consist of a $150 million term loan and a $50 million revolving credit facility (together, referred to as the “Loans”), both of which will mature in 2021. A short period after the implementation of Bill C-45 in October 2018, the Company may request an increase of up to a further $45 million to the term loan subject to agreement by BMO and satisfaction of certain legal and business conditions. BMO will also be providing up to $5 million in other credit instruments. Closing of the debt facility is subject to completion of final due diligence, negotiation of definitive documentation, and satisfaction of conditions precedent customary to a financing of this nature.

The debt facility will be primarily secured by Aurora’s production facilities, including Aurora Sky, Aurora Mountain, and Aurora Vie. Strategically located at Edmonton International Airport, Aurora Sky is the world’s most technologically advanced cannabis facility, projected to produce in excess of 100,000 kg per year of high-quality cannabis at low per gram costs, and slated to deliver its first harvest this week.

“Having successfully met all of BMO’s stringent risk assessment and other due diligence criteria to establish this facility reflects well on the maturity, progress and prospects of Aurora, as well as the quality and economic value of our production facilities,” said Terry Booth, CEO. “This is by far the largest traditional debt facility in the cannabis industry to date. The funds provide us additional fuel to complement our end-to-end portfolio of vertically integrated, geographically and horizontally diversified assets, aimed at building a pre-eminent global cannabis company with a superior margin profile.”

Glen Ibbott, CFO of Aurora, added, “The shift to traditional debt financing is significant. Our cost of capital continues to decrease, providing us a distinct competitive advantage as we execute on our growth strategy. The non-dilutive nature and attractive pricing are consistent with Aurora’s commitment to generating shareholder value. We believe this is a major milestone in the cannabis industry and a validation of our operational effectiveness. It also marks an exciting new stage of our long-term relationship with BMO, a Tier 1 bank with a sterling domestic and international reputation.”

The Loans can be repaid without penalty at Aurora’s discretion. The pricing of the Loans is a set margin over the BMO CAD Prime Rate or a Bankers’ Acceptance of appropriate term. Based on the current BMO CAD Prime Rate, the interest payable is expected to be in the mid to high 4% per annum range over the term of the Loans.

]]> https://mjshareholders.com/pivot-pharma-to-file-investigational-new-drug-ind-application-with-u-s-fda-for-pvt-005/ Wed, 27 Jun 2018 19:58:21 +0000 http://www.cannabisfn.com/?p=953546

Cannabinoid Topical Cream For Treatment Of Female Hypoactive Sexual Desire Disorder

VANCOUVER, June 27, 2018 /CNW/ – Pivot Pharmaceuticals Inc. (CSE: PVOT / OTCQB: PVOTF / FRA: NPAT) (“Pivot” or the “Company”) is pleased to announce that it will file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) and Clinical Trial Application (CTA) with Health Canada to begin human clinical trials of PVT-005, the Company’s pharmaceutical drug candidate for the treatment of Female Hypoactive Sexual Desire Disorder (HSDD).

HSDD, the most common type of female sexual dysfunction (“FSD”), affects approximately 12 million women in the U.S. alone. The condition is characterized by low sexual desire and marked distress which are not attributable to existing medical, pharmacologic, psychiatric, or relationship issues. Approximately 6 million pre-menopausal women meet the diagnosis for acquired, generalized HSDD.

Using Pivot’s drug formulation and delivery platform technologies, the Company will develop and aim to commercialize a topical cream containing cannabinoids (“PVT-N005”) for perimenopausal, menopausal and post-menopausal women who have noticed a decline in sexual desire and response. While erectile dysfunction in men has been extensively researched, very little has been completed on female sexual dysfunction which can involve reduced sex drive, difficulty becoming aroused, vaginal dryness, lack of orgasm and decreased sexual satisfaction.

“In vitro results from our contract research laboratory indicated that PVT-005 (1% CBD – formulated) was highly bioavailable. Additional studies showed that the product did not cause any local irritation in an in-vivo model. We have also successfully conducted degradation and stability studies with the product candidate. As a result, we have selected a drug candidate for HSDD which we will move to IND and CTA filings with health authorities to conduct clinical trials in women. Our cGMP manufacturing partner, BioV Pharma Inc., will produce the clinical trial material made using our formulation technology,” said Dr. Joseph Borovsky, Pivot’s Executive Vice President, Product Development.

Pivot’s Chief Medical Officer, Dr. Wolfgang Renz stated “Given that our topical delivery system has previously shown to be safe and well tolerated when administered intravaginally in a clinical trial setting, we believe that we can deliver cannibinoids to target female sexual dysfunction, a large unmet medical need with a multi-billion dollar market. The use of a highly bioavailable and safe topical cannabinoid is a great option for treating this indication, avoiding the known side effects of existing therapeutics.”

While men have had Viagra, Cialis, and Levitra to address their sexual dysfunction issues, finding a solution for FSD has been more complicated. The market for female sexual dysfunction drugs is believed to be larger than the market for male sexual dysfunction treatments since the percentage of women with FSD between the ages 18 and 59 is higher than that for men. The FSD market in the U.S. is estimated to exceed $4 billion with over 50 million potential sufferers.¹

About Pivot Pharmaceuticals Inc.

Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or “Pivot Green Stream”), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. Pivot’s wholly-owned U.S. subsidiary, Pivot Naturals, LLC, based in Costa Mesa, California, will manufacture and supply finished powderized cannabis products such as food additives, capsules, bulk powder and stick packs to the California market. PGS has acquired worldwide rights to “RTIC” Ready-To-Infuse Cannabis oil-to-powder technology, BiPhasix Dermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products. For more information please visit www.PivotPharma.com

Cautionary Statement

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate, believe, estimate, expect, intend, and similar expressions, as they relate to Pivot Pharmaceuticals Inc., Pivot Green Stream Health Solutions Inc., Pivot Naturals, LLC, or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, such as the failure to meet the conditions imposed by the CSE or other securities regulators, the level of business and consumer spending, the amount of sales of Pivot’s products, statements with respect to internal expectations, the competitive environment within the industry, the ability of Pivot to continue to expand its operations, the level of costs incurred in connection with Pivot’s expansion efforts, economic conditions in the industry, and the financial strength of Pivot’s customers and suppliers. Pivot does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

---

¹https://www.researchgate.net/publication/7977139_Female_sexual_dysfunction

 View original content:http://www.prnewswire.com/news-releases/pivot-pharma-to-file-investigational-new-drug-ind-application-with-us-fda-for-pvt-005-300672985.html

SOURCE Pivot Pharmaceuticals Inc.

View original content: http://www.newswire.ca/en/releases/archive/June2018/27/c8506.html

Pivot Pharmaceuticals Inc., Patrick Frankham, PhD, MBA, Chief Executive Officer, Email: Info@PivotPharma.com; Virtus Advisory Group, Investor Relations, Email: Pivot@virtusadvisor.com, Phone: 416-644-5081Copyright CNW Group 2018

]]> https://mjshareholders.com/biotrackthc-launches-integration-with-dataowl-for-online-ordering-crm-digital-menus/ Tue, 26 Jun 2018 23:13:10 +0000 http://www.cannabisbusinesstimes.com/Article/biotrackthc-launches-integration-dataowl

LAFAYETTE, Colo. — The political rise of Colorado’s cannabis industry is, in essence, the story of Garrett Hause’s alfalfa farm.

Mr. Hause, a broad-shouldered, 25-year-old horticulturist who tills his family’s land in the shadow of the snow-capped Rocky Mountains, said he was never particularly interested in politics — that is, until voters legalized cannabis in 2012. He started familiarizing himself with the stringent state regulations that govern the industry. He and a friend then created Elation Cannabis Company, which uses a section of the family’s soil to grow hemp.

One afternoon last week, ahead of Tuesday’s primary in the Colorado governor’s race, Mr. Hause hosted one of the leading Democratic candidates, Representative Jared Polis, and reflected on his journey from political ambivalence to activism.

Read more

Top photo courtesy of Adobe Stock

]]>